AGI Therapeutics Limited
Records under this name other than patents AGI Therapeutics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to AGI Therapeutics Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,825,106 | Modified release formulations and methods of treating inflammatory bowel disease Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,737,133 | Formulations and methods of treating inflammatory bowel disease Formerly held Term ended Term ended Sep 17, 2024 · USPTO record | Term ended | Term ended Sep 17, 2024 | USPTO record |
| US 7,928,092 | Formulations and methods of treating inflammatory bowel disease Formerly held Term ended Term ended Sep 1, 2024 · USPTO record | Term ended | Term ended Sep 1, 2024 | USPTO record |
| US 6,849,661 | Treatment of Abnormal Increases in Gastrointestinal Motility with (R)-Verapamil Formerly held Term ended Term ended Nov 24, 2022 · Medium confidence | Term ended | Term ended Nov 24, 2022 | Medium confidence |
| US 9,040,591 | Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof Formerly held Lapsed on the fee record Ended May 26, 2019 · USPTO record | Lapsed on the fee record | Ended May 26, 2019 | USPTO record |
| US 7,098,232 | Treatment and prevention of gastrointestinal disease using antagonists of partial agonists of 5HT1a receptors Formerly held Lapsed on the fee record Ended Aug 29, 2010 · USPTO record | Lapsed on the fee record | Ended Aug 29, 2010 | USPTO record |